# Daktronics Inc: financial statements, quarterly

DAKT · Nasdaq · CIK 915779 · [Consumer discretionary](/sectors/consumer-discretionary.md) · fiscal year ends May 1

Pages: [Overview](/companies/dakt.md) · [Financials](/companies/dakt/financials.md) · [Filings](/companies/dakt/filings.md) · [Insiders](/companies/dakt/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/dakt/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2024 (2023-10-28) | Q3 FY2024 (2024-01-27) | Q4 FY2024 (2024-04-27) | Q1 FY2025 (2024-07-27) | Q2 FY2025 (2024-10-26) | Q3 FY2025 (2025-01-25) | Q4 FY2025 (2025-04-26) | Q1 FY2026 (2025-08-02) | Q2 FY2026 (2025-11-01) | Q3 FY2026 (2026-01-31) | Q4 FY2026 (2026-05-02) | Q1 FY2027 (2026-08-01) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [199](/filings/0000915779-24-000152.md) | [170](/filings/0000915779-25-000061.md) | [216 d](/filings/0001628280-26-045262.md) | [226](/filings/0000915779-25-000174.md) | [208](/filings/0001628280-25-056270.md) | [150](/filings/0001628280-26-014553.md) | [173 d](/filings/0001628280-26-045262.md) | [219](/filings/0001628280-26-060057.md) | [229](/filings/0001628280-25-056270.md) | [182](/filings/0001628280-26-014553.md) | [209 d](/filings/0001628280-26-045262.md) | [235](/filings/0001628280-26-060057.md) |
| Cost of revenue | $m | [145](/filings/0000915779-24-000152.md) | [129](/filings/0000915779-25-000061.md) | [161 d](/filings/0001628280-26-045262.md) | [166](/filings/0000915779-25-000174.md) | [152](/filings/0001628280-25-056270.md) | [113](/filings/0001628280-26-014553.md) | [129 d](/filings/0001628280-26-045262.md) | [154](/filings/0001628280-26-060057.md) | [167](/filings/0001628280-25-056270.md) | [138](/filings/0001628280-26-014553.md) | [150 d](/filings/0001628280-26-045262.md) | [163](/filings/0001628280-26-060057.md) |
| Gross profit | $m | [54.2](/filings/0000915779-24-000152.md) | [41.7](/filings/0000915779-25-000061.md) | [55.4 d](/filings/0001628280-26-045262.md) | [59.7](/filings/0000915779-25-000174.md) | [55.9](/filings/0001628280-25-056270.md) | [36.8](/filings/0001628280-26-014553.md) | [43.1 d](/filings/0001628280-26-045262.md) | [65.1](/filings/0001628280-26-060057.md) | [61.8](/filings/0001628280-25-056270.md) | [43.6](/filings/0001628280-26-014553.md) | [58.5 d](/filings/0001628280-26-045262.md) | [71.6](/filings/0001628280-26-060057.md) |
| Research and development | $m | [9.2](/filings/0000915779-24-000152.md) | [8.8](/filings/0000915779-25-000061.md) | [9.3 d](/filings/0001628280-26-045262.md) | [9.6](/filings/0000915779-25-000174.md) | [9.8](/filings/0001628280-25-056270.md) | [9.4](/filings/0001628280-26-014553.md) | [10.0 d](/filings/0001628280-26-045262.md) | [10.7](/filings/0001628280-26-060057.md) | [10.4](/filings/0001628280-25-056270.md) | [10.5](/filings/0001628280-26-014553.md) | [11.8 d](/filings/0001628280-26-045262.md) | [12.1](/filings/0001628280-26-060057.md) |
| Operating income | $m | [19.4](/filings/0000915779-24-000152.md) | [8.0](/filings/0000915779-25-000061.md) | [19.4 d](/filings/0001628280-26-045262.md) | [22.7](/filings/0000915779-25-000174.md) | [15.8](/filings/0001628280-25-056270.md) | [(3.6)](/filings/0001628280-26-014553.md) | [(1.7) d](/filings/0001628280-26-045262.md) | [23.3](/filings/0001628280-26-060057.md) | [21.6](/filings/0001628280-25-056270.md) | [1.9](/filings/0001628280-26-014553.md) | [14.1 d](/filings/0001628280-26-045262.md) | [24.9](/filings/0001628280-26-060057.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [4.0](/filings/0000915779-24-000152.md) | [1.9](/filings/0000915779-25-000061.md) | [4.6 d](/filings/0001628280-26-045262.md) | [5.2](/filings/0000915779-25-000174.md) | [3.8](/filings/0001628280-25-056270.md) | [(0.7)](/filings/0001628280-26-014553.md) | [(4.0) d](/filings/0001628280-26-045262.md) | [5.8](/filings/0001628280-26-060057.md) | [4.4](/filings/0001628280-25-056270.md) | [0.5](/filings/0001628280-26-014553.md) | [2.3 d](/filings/0001628280-26-045262.md) | [6.2](/filings/0001628280-26-060057.md) |
| Net income | $m | [2.2](/filings/0000915779-25-000061.md) | [10.7](/filings/0000915779-25-000061.md) | [2.5 d](/filings/0001628280-26-045262.md) | [(4.9)](/filings/0001628280-26-014553.md) | [21.4](/filings/0001628280-26-014553.md) | [(17.2)](/filings/0001628280-26-014553.md) | [(9.4) d](/filings/0001628280-26-045262.md) | [16.5](/filings/0001628280-26-060057.md) | [17.5](/filings/0001628280-26-014553.md) | [3.0](/filings/0001628280-26-014553.md) | [8.4 d](/filings/0001628280-26-045262.md) | [19.4](/filings/0001628280-26-060057.md) |
| Diluted EPS | $ per share | [0.05](/filings/0000915779-24-000152.md) | [0.09](/filings/0000915779-25-000061.md) | not reported | [(0.11)](/filings/0000915779-25-000174.md) | [0.22](/filings/0001628280-25-056270.md) | [(0.36)](/filings/0001628280-26-014553.md) | not reported | [0.33](/filings/0001628280-26-060057.md) | [0.35](/filings/0001628280-25-056270.md) | [0.06](/filings/0001628280-26-014553.md) | not reported | [0.40](/filings/0001628280-26-060057.md) |
| Basic EPS | $ per share | [0.05](/filings/0000915779-24-000152.md) | [0.23](/filings/0000915779-25-000061.md) | not reported | [(0.11)](/filings/0000915779-25-000174.md) | [0.46](/filings/0001628280-25-056270.md) | [(0.36)](/filings/0001628280-26-014553.md) | not reported | [0.34](/filings/0001628280-26-060057.md) | [0.36](/filings/0001628280-25-056270.md) | [0.06](/filings/0001628280-26-014553.md) | not reported | [0.40](/filings/0001628280-26-060057.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2024 (2023-10-28) | Q3 FY2024 (2024-01-27) | FY2024 (2024-04-27) | Q1 FY2025 (2024-07-27) | Q2 FY2025 (2024-10-26) | Q3 FY2025 (2025-01-25) | FY2025 (2025-04-26) | Q1 FY2026 (2025-08-02) | Q2 FY2026 (2025-11-01) | Q3 FY2026 (2026-01-31) | FY2026 (2026-05-02) | Q1 FY2027 (2026-08-01) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [64.7](/filings/0000915779-24-000152.md) | [76.8](/filings/0000915779-25-000061.md) | [81.3](/filings/0001628280-26-045262.md) | [96.8](/filings/0000915779-25-000174.md) | [134](/filings/0000915779-24-000152.md) | [132](/filings/0000915779-25-000061.md) | [128](/filings/0001628280-26-045262.md) | [137](/filings/0000915779-25-000174.md) | [150](/filings/0001628280-25-056270.md) | [144](/filings/0001628280-26-014553.md) | [132](/filings/0001628280-26-060057.md) | [155](/filings/0001628280-26-060057.md) |
| Current assets | $m | [386](/filings/0000915779-23-000133.md) | [376](/filings/0000915779-24-000007.md) | [402](/filings/0000915779-25-000102.md) | [427](/filings/0000915779-24-000083.md) | [423](/filings/0000915779-24-000152.md) | [394](/filings/0000915779-25-000061.md) | [381](/filings/0001628280-26-045262.md) | [429](/filings/0000915779-25-000174.md) | [430](/filings/0001628280-25-056270.md) | [426](/filings/0001628280-26-014553.md) | [448](/filings/0001628280-26-060057.md) | [501](/filings/0001628280-26-060057.md) |
| Total assets | $m | [511](/filings/0000915779-23-000133.md) | [499](/filings/0000915779-24-000007.md) | [528](/filings/0000915779-25-000102.md) | [554](/filings/0000915779-24-000083.md) | [552](/filings/0000915779-24-000152.md) | [524](/filings/0000915779-25-000061.md) | [503](/filings/0001628280-26-045262.md) | [546](/filings/0000915779-25-000174.md) | [548](/filings/0001628280-25-056270.md) | [546](/filings/0001628280-26-014553.md) | [554](/filings/0001628280-26-060057.md) | [607](/filings/0001628280-26-060057.md) |
| Current liabilities | $m | [190](/filings/0000915779-23-000133.md) | [170](/filings/0000915779-24-000007.md) | [192](/filings/0000915779-25-000102.md) | [197](/filings/0000915779-24-000083.md) | [180](/filings/0000915779-24-000152.md) | [162](/filings/0000915779-25-000061.md) | [172](/filings/0001628280-26-045262.md) | [208](/filings/0000915779-25-000174.md) | [193](/filings/0001628280-25-056270.md) | [192](/filings/0001628280-26-014553.md) | [194](/filings/0001628280-26-060057.md) | [231](/filings/0001628280-26-060057.md) |
| Total liabilities | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Long-term debt | $m | [55.1](/filings/0000915779-23-000133.md) | [48.5](/filings/0000915779-24-000007.md) | [53.2](/filings/0000915779-25-000102.md) | [74.5](/filings/0000915779-24-000083.md) | [63.9](/filings/0000915779-24-000152.md) | [41.0](/filings/0000915779-25-000061.md) | [10.5](/filings/0001628280-26-045262.md) | [10.1](/filings/0000915779-25-000174.md) | [9.8](/filings/0001628280-25-056270.md) | [9.9](/filings/0001628280-26-014553.md) | [9.6](/filings/0001628280-26-060057.md) | [9.4](/filings/0001628280-26-060057.md) |
| Current portion of debt | $m | [1.5](/filings/0000915779-23-000133.md) | [1.5](/filings/0000915779-24-000007.md) | [1.5](/filings/0000915779-25-000102.md) | [1.5](/filings/0000915779-24-000083.md) | [1.5](/filings/0000915779-24-000152.md) | [1.5](/filings/0000915779-25-000061.md) | [1.5](/filings/0001628280-26-045262.md) | [1.5](/filings/0000915779-25-000174.md) | [1.5](/filings/0001628280-25-056270.md) | [1.2](/filings/0001628280-26-014553.md) | [1.2](/filings/0001628280-26-060057.md) | [1.2](/filings/0001628280-26-060057.md) |
| Shareholders' equity | $m | [223](/filings/0000915779-25-000061.md) | [236](/filings/0000915779-25-000061.md) | [239](/filings/0001628280-26-045262.md) | [238](/filings/0001628280-26-014553.md) | [261](/filings/0001628280-26-014553.md) | [272](/filings/0001628280-26-014553.md) | [272](/filings/0001628280-26-060057.md) | [280](/filings/0001628280-26-060057.md) | [297](/filings/0001628280-26-014553.md) | [294](/filings/0001628280-26-014553.md) | [301](/filings/0001628280-26-060057.md) | [318](/filings/0001628280-26-060057.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: not reported
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2024 (2023-10-28) | Q3 FY2024 (2024-01-27) | Q4 FY2024 (2024-04-27) | Q1 FY2025 (2024-07-27) | Q2 FY2025 (2024-10-26) | Q3 FY2025 (2025-01-25) | Q4 FY2025 (2025-04-26) | Q1 FY2026 (2025-08-02) | Q2 FY2026 (2025-11-01) | Q3 FY2026 (2026-01-31) | Q4 FY2026 (2026-05-02) | Q1 FY2027 (2026-08-01) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [25.1 d](/filings/0000915779-24-000152.md) | [9.5 d](/filings/0000915779-25-000061.md) | [9.5 d](/filings/0001628280-26-045262.md) | [19.5](/filings/0000915779-25-000174.md) | [43.3 d](/filings/0001628280-25-056270.md) | [12.0 d](/filings/0001628280-26-014553.md) | [22.9 d](/filings/0001628280-26-045262.md) | [26.1](/filings/0001628280-26-060057.md) | [16.5 d](/filings/0001628280-25-056270.md) | [11.7 d](/filings/0001628280-26-014553.md) | [(5.1) d](/filings/0001628280-26-045262.md) | [31.4](/filings/0001628280-26-060057.md) |
| Capital expenditure | $m | [4.7 d](/filings/0000915779-24-000152.md) | [4.4 d](/filings/0000915779-25-000061.md) | [3.4 d](/filings/0001628280-26-045262.md) | [5.1](/filings/0000915779-25-000174.md) | [5.4 d](/filings/0001628280-25-056270.md) | [4.2 d](/filings/0001628280-26-014553.md) | [4.8 d](/filings/0001628280-26-045262.md) | [4.3](/filings/0001628280-26-060057.md) | [2.5 d](/filings/0001628280-25-056270.md) | [3.6 d](/filings/0001628280-26-014553.md) | [4.5 d](/filings/0001628280-26-045262.md) | [4.1](/filings/0001628280-26-060057.md) |
| Dividends paid | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $m | not reported | not reported | [0.0 d](/filings/0001628280-26-045262.md) | [0.0](/filings/0000915779-25-000174.md) | [0.0 d](/filings/0001628280-25-056270.md) | [9.0 d](/filings/0001628280-26-014553.md) | [20.5 d](/filings/0001628280-26-045262.md) | [10.7](/filings/0001628280-26-060057.md) | [1.6 d](/filings/0001628280-25-056270.md) | [10.6 d](/filings/0001628280-26-014553.md) | [2.8 d](/filings/0001628280-26-045262.md) | [4.4](/filings/0001628280-26-060057.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: not reported
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q2 FY2023 (2022-10-29) | Q3 FY2023 (2023-01-28) | Q1 FY2024 (2023-07-29) | Q2 FY2024 (2023-10-28) | Q3 FY2024 (2024-01-27) | Q1 FY2025 (2024-07-27) | Q2 FY2025 (2024-10-26) | Q3 FY2025 (2025-01-25) | Q1 FY2026 (2025-08-02) | Q2 FY2026 (2025-11-01) | Q3 FY2026 (2026-01-31) | Q1 FY2027 (2026-08-01) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [45.3](/filings/0000915779-23-000133.md) | [45.4](/filings/0000915779-24-000007.md) | [46.2](/filings/0000915779-24-000083.md) | [46.7](/filings/0000915779-24-000152.md) | [50.8](/filings/0000915779-25-000061.md) | [46.3](/filings/0000915779-25-000174.md) | [51.7](/filings/0001628280-25-056270.md) | [47.8](/filings/0001628280-26-014553.md) | [49.7](/filings/0001628280-26-060057.md) | [49.4](/filings/0001628280-25-056270.md) | [49.3](/filings/0001628280-26-014553.md) | [48.9](/filings/0001628280-26-060057.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 48,092,650 at 2026-08-24, from the cover of the [10-Q filed 2026-09-02](/filings/0001628280-26-060057.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:28 ET. No prices; not investment advice.